Rave Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.20 M
- Paid Up Capital ₹ 0.20 M
- Company Age 24 Year, 3 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 1.05 M
- Revenue Growth 25.61%
- Profit Growth 27.93%
- Ebitda -102.17%
- Net Worth 7.70%
- Total Assets -25.71%
About Rave Pharmaceuticals
Rave Pharmaceuticals Private Limited (RPPL) is a Private Limited Indian Non-Government Company incorporated in India on 03 November 2000 and has a history of 24 years and three months. Its registered office is in Shahjahanpur, Uttar Pradesh, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.20 M and a paid-up capital of Rs 0.20 M.
The company currently has active open charges totaling ₹1.05 M.
Sunil Gupta, Vandana Gupta, and Sachin Gupta serve as directors at the Company.
Company Details
-
Location
Shahjahanpur, Uttar Pradesh, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
-
Website
-
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U24232UP2000PTC025721
-
Company No.
025721
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
03 Nov 2000
-
Date of AGM
28 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Kanpur
Industry
Who are the key members and board of directors at Rave Pharmaceuticals?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sunil Gupta
|
Managing Director | 09-Jun-2003 | Current |
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
|
Vandana Gupta
|
Director | 07-Apr-2003 | Current |
|
Sachin Gupta
|
Director | 03-Sep-2012 | Current |
Financial Performance of Rave Pharmaceuticals.
Rave Pharmaceuticals Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 25.61% increase. The company also saw a substantial improvement in profitability, with a 27.93% increase in profit. The company's net worth moved up by a moderate rise of 7.7%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Rave Pharmaceuticals?
In 2018, Rave Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹1.05 M
₹0
Charges Breakdown by Lending Institutions
- Dena Bank : 0.06 Cr
- : 0.05 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 31 Oct 2014 | Dena Bank | ₹0.55 M | Open |
| 23 May 2013 | ₹0.50 M | Open |
How Many Employees Work at Rave Pharmaceuticals?
Unlock and access historical data on people associated with Rave Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Rave Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Rave Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.